Results 131 to 140 of about 3,975 (165)

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China. [PDF]

Front Immunol
Yang H, Yu Q, Li M, Liu M.
europepmc   +1 more source

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. [PDF]

J Infect Dis
Diamond TL, Grandhi A, Fuszard M, Xu Y, Nwoke U, Zhang Y, Klopfer SO, Eves K, Benner J, Li M, Greaves W, Lahoulou R, Kim J, Fox MC, Asante-Appiah E.   +14 more
europepmc   +1 more source

Healthcare Resource Consumption and Related Costs of People Living with HIV and Antiviral Treatment: A Retrospective Observational Study in Italy. [PDF]

Diseases
Degli Esposti L, Mazzoni S, Cappuccilli M, Maggiolo F, Caputo SL, Nozza S, Taramasso L, Marra A, Pittorru M.   +8 more
europepmc   +1 more source

Inflammatory Biomarkers Decay After First‐Line Antiretroviral Therapy Initiation With Dolutegravir/Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide in Persons With HIV: A Substudy of a Randomized Clinical Trial

Health Science Reports
Analuz Fernandez, Sofía Scevola, Raul Rigo Bonin, Maria Saumoy, Arkaitz Imaz, Daniel Podzamczer, Juan Tiraboschi   +6 more
doaj   +1 more source

Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report. [PDF]

Front Immunol
Wang W, Tang S, Yang J, Wen Y.
europepmc   +1 more source

Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks. [PDF]

J Acquir Immune Defic Syndr
VanderVeen LA, Selzer L, Chang S, Li J, Diamond TL, Asante-Appiah E, Llamoso C, Rhee MS, Callebaut C.   +8 more
europepmc   +1 more source

Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy. [PDF]

BMC Infect Dis
Li Q, Li J, Gao C, Zhao Y, Zhu L, Xiao J, Zhang F.   +6 more
europepmc   +1 more source

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review. [PDF]

Viruses
Margot NA, Callebaut C.
europepmc   +1 more source

Repurposing approved drugs as Pendrin (<i>SLC26A4</i>) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation. [PDF]

Front Pharmacol
Lai J, Zhao D, Wang X, Wang B, Nan J.
europepmc   +1 more source

Contemporary Single and Multi-Tablet HIV Treatment Regimens Are Associated With Similar Levels of Viral Suppression. [PDF]

Open Forum Infect Dis
Yao K, Lawson L, Pistoresi R, Sullivan D, Golden MR.   +4 more
europepmc   +1 more source